News - 24 Feb `23Incyte wins EU nod for vitiligo cream Opzelura

New

Great news for the vitiligo community in the EU!

Incyte has just announced in a press-release that ruxolitinib cream (Opzelura™) has received a positive opinion from the European Medicines Agency (EMA) committee for the treatment of vitiligo with facial involvement.

The green light opens the fast track way for it to become the first ‘official’ vitiligo therapy available in the EU. Incyte has been eagerly awaiting approval in the EU ever since the it’s drug was registered by the US FDA in July 2022.

Opzelura, a 1.5% ruxolitinib cream, is a sister medication to Incyte's JAK inhibitor, Jakafi. It is used to treat nonsegmental vitiligo in patients ages 12 and older, with primarily facial involvement. The cream is meant to be applied twice a day on affected areas of up to 10% of the body’s surface area, and patients may need to use it for up to 24 weeks in order to see the best results.

More details

Vitiligo-Opzelura-pre-approval-EU

 



      FAQOther Questions

      • Red Wine and Vitiligo

        Recent research has revealed intriguing findings about the potential protective effects of red wine against vitiligo, using a genetic approach to study health outcomes. Red Win...

      • Is there a link between vitiligo and depression?

        Depression and anxiety are often linked with vitiligo, significantly impacting a person’s quality of life. The connection stems from the shared origin of the skin and brain duri...

      • How can I explain vitiligo to my children?

        Vitiligo can be confusing for children because it doesn’t resemble an "illness" in the typical sense. Choosing the right way to explain it depends on your child’s age and maturi...